Yanyan Lou, M.D., Ph.D.
Dr. Yanyan Lou is a medical oncologist and researcher with a special focus on lung cancer and the development of CAR-T cell therapies for the treatment of thoracic cancers. She treats patients with both lung cancer and mesothelioma at the Mayo Clinic in Jacksonville, Florida.[1]
Education and Career
Dr. Lou earned her medical degree at Henan Medical University in China and her Ph.D. in Oncology and Tumor Immunology at the West China University of Medical Science.
She completed her first postdoctoral fellowship in Surgery at the National Cancer Institute of the National Institutes of Health, then pursued another postdoctoral fellowship in Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center.
Dr. Lou then completed a residency in Internal Medicine at the University of Texas Southwestern Medical School and a clinical fellowship there in Hematology/Oncology before joining the Mayo Clinic in Florida.[1]
Dr. Lou is now an internist and oncologist at the Mayo Clinic in Jacksonville, Florida. She is part of the Head and Neck Cancer Program, Lung Cancer Program, and CAR-T Cell Therapy Program. Dr. Lou specializes in treating patients with thoracic cancers, including pleural mesothelioma and lung cancer.
She is particularly focused on immunotherapy and targeted drug therapy to improve patient outcomes and is actively involved in several clinical trials investigating their use, as well as other novel investigational therapies for thoracic cancers.
Dr. Lou holds two leadership positions at the Mayo Clinic in Jacksonville: Associate Director of the Early Cancer Therapeutics Program and Vice Chair of Research for the Division of Hematology and Medical Oncology.[2]
Research
Dr. Lou’s research interests are varied, but all revolve around the treatment of lung cancer and other thoracic malignancies, improving patient outcomes, and developing new, more effective treatments for these difficult-to-treat diseases.
She is currently engaged in an interventional study of the use of pembrolizumab with or without anetumab ravtansine in treating patients with mesothelin-positive pleural mesothelioma.[3]
She is a highly respected researcher and has published many studies on non-small cell lung cancer, immunotherapy, mesothelioma, tumor microenvironments, nivolumab, and other topics relevant to patients diagnosed with lung cancer or malignant mesothelioma.
Awards and Memberships
Dr. Lou has received multiple awards and honors throughout her career, including:
- Paul Calabresi Career Development Award for Clinical Oncology from the National Cancer Institute
- Eveleigh Family Career Development Award from the Mayo Clinic in Florida
- Jan and Deanie Stein Career Development Award from the Mayo Clinic in Florida
- Young Investigator Award from the Chinese-American Hematologist Oncologist Network
- ASCO Young Investigator Award from the American Society of Clinical Oncology
She is an active member of the Mayo Clinic NCI-Designated Comprehensive Cancer Center, a Committee Member of the Alliance for Clinical Trials in Oncology, a member of the MCCC Council for Minority Participation in Cancer Research, and a member of the Data Safety Monitoring Board.[1]
